Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA Baseline For Rx Costs: 7% Of Health Care Spending Is On Brands

Executive Summary

Brand name drugs account for 7% of health care spending, Pharmaceutical Research & Manufacturers of America President Alan Holmer said during The Economist's Annual Pharmaceutical Roundtable in Philadelphia Nov. 19

You may also be interested in...

Foreign Generic Drug Use Is Key To Rx Price Equity, FDA’s McClellan Says

Foreign countries could redirect billions of dollars into medical innovation by encouraging generic drug use, FDA Commissioner McClellan suggested in a speech to the Drug Information Association in Ottawa, Canada Nov. 18

PhRMA Priorities After Medicare Rx: “Access And Affordability”

The Pharmaceutical Research & Manufacturers of America is adding "affordability" to "access" as a key theme of its advocacy agenda

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts